RT Journal Article
T1 COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding.
A1 Demelo Rodríguez, Pablo
A1 Alonso Beato, Rubén
A1 Jara Palomares, Luis
A1 Galeano Valle, Francisco
A1 BuraR iviere, Alessandra
A1 Visonà, Adriana
A1 Iria, Francisco
A1 Vidal, Gemma
A1 López Ruiz, Antonio
A1 Monreal, Manuel
AB BackgroundComplications under anticoagulant treatment in patients with COVID-19-associated venous thromboembolism (VTE) have not been consistently reported.ObjectivesThis study aimed to compare the 90-day rates of VTE recurrences and major bleeding in patients with COVID-19-associated VTE versus those with VTE without COVID-19.MethodsWe used the RIETE registry to compare the 3-month outcomes in patients with COVID-19-associated VTE versus those with VTE without COVID-19.ResultsThe study included 1,747 patients with COVID-19-associated VTE and 8,711 with VTE without COVID-19. Patients with COVID-19-associated VTE were more likely to be hospitalized at baseline and to present with pulmonary embolism. During the first 90 days, 123 patients (1.17%) developed VTE recurrences, and 266 (2.54%) experienced major bleeding. Patients with COVID-19-associated VTE had a similar rate of VTE recurrences (0.9% vs 1.2%) but a higher rate of major bleeding (4.6% vs 2.1%; P < .001) than those without COVID-19. Multivariable analysis adjusted for competing risks showed that patients with COVID-19-associated VTE had an increased risk of major bleeding (subhazard ratio, 1.395; 95% confidence interval, 1.037-1.877). The 30-day mortality after major bleeding was 26.3% in patients with COVID-19-associated VTE and 17.7% in those without COVID-19.ConclusionPatients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulation. In VTE patients without COVID-19, both rates were similar. These findings highlight the importance of carefully monitoring and optimizing anticoagulation in these patients.
PB Elsevier
SN 2475-0379
YR 2023
FD 2023-09-20
LK https://hdl.handle.net/20.500.14352/129271
UL https://hdl.handle.net/20.500.14352/129271
LA eng
NO Demelo-Rodríguez P, Alonso-Beato R, Jara-Palomares L, Galeano-Valle F, Bura-Riviere A, Visonà A, Francisco I, Vidal G, López-Ruiz A, Monreal M; RIETE Investigators. COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding.  Res Pract Thromb Haemost. 2023;7(7):102206. doi: 10.1016/j.rpth.2023.102206. PMID: 37840687; PMCID: PMC10569976.
DS Docta Complutense
RD 31 dic 2025